{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:20:17Z","timestamp":1790616017814,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The phase III European Organization for Research and Treatment of Cancer 55874 study has shown that external beam radiotherapy (EBRT) given as adjuvant treatment decreased locoregional recurrences from 40% to 20% in patients (pts) with localized uterine sarcomas (US). No data exist, however, on the place of brachytherapy (BT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Material and Methods<\/jats:title>\n                  <jats:p>We conducted a single-center retrospective analysis of pts receiving adjuvant BT of the vaginal vault based on the vaginal mold technique as part of their multimodal adjuvant treatment for a high-grade US from 1985 to 2015. Treatment characteristics, patterns of relapse, and toxicity were examined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median follow-up time was 5.5 years. A total of 98 pts with high-grade US were identified: 81 leiomyosarcomas and 17 undifferentiated sarcomas. Postoperative chemotherapy was delivered in 53 pts. Median dose of EBRT was 45 Gy in 25 fractions. High-dose rate, low-dose rate, and pulsed-dose rate techniques were used in 66, 31, and 1 pts, respectively. At last follow-up, six pts (6.1%) experienced a locoregional relapse as first event. The International Federation of Gynecology and Obstetrics stage and the tumor size were associated with a higher probability of local relapse. When focusing on pts with stage I-III disease, 5-year overall survival was 77% (95% confidence interval: 67%\u201387%) and 5-year survival without locoregional failure was 91% (83%\u201398%). Toxicities were mild to moderate, with only four acute grade 3 toxicities and two grade 3 late effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Vaginal vault BT as part of a multimodal adjuvant treatment was associated with a high locoregional control rate and with acceptable side effects in localized high-grade US.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0204","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T02:20:18Z","timestamp":1486520418000},"page":"182-188","source":"Crossref","is-referenced-by-count":8,"title":["Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment"],"prefix":"10.1093","volume":"22","author":[{"given":"Pierre","family":"Annede","sequence":"first","affiliation":[{"name":"Brachytherapy Unit, Gustave Roussy, Villejuif, France"},{"name":"Department of Radiotherapy, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gouy","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Mazeron","sequence":"additional","affiliation":[{"name":"Brachytherapy Unit, Gustave Roussy, Villejuif, France"},{"name":"Department of Radiotherapy, Gustave Roussy, Villejuif, France"},{"name":"INSERM 1030, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Bentivegna","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Maroun","sequence":"additional","affiliation":[{"name":"Brachytherapy Unit, Gustave Roussy, Villejuif, France"},{"name":"Department of Radiotherapy, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Petit","sequence":"additional","affiliation":[{"name":"Brachytherapy Unit, Gustave Roussy, Villejuif, France"},{"name":"Department of Radiotherapy, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Dumas","sequence":"additional","affiliation":[{"name":"Brachytherapy Unit, Gustave Roussy, Villejuif, France"},{"name":"Department of Radiotherapy, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Genestie","sequence":"additional","affiliation":[{"name":"Department of Pathology Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lhomm\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Gustave Roussy, Villejuif, France"},{"name":"INSERM 1030, Gustave Roussy Cancer Campus, Villejuif, France"},{"name":"Universit\u00e9 Paris-Sud, SIRIC SOCRATES, Facult\u00e9 de M\u00e9decine, Le Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Morice","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gustave Roussy, Villejuif, France"},{"name":"Universit\u00e9 Paris-Sud, SIRIC SOCRATES, Facult\u00e9 de M\u00e9decine, Le Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Haie-Meder","sequence":"additional","affiliation":[{"name":"Brachytherapy Unit, Gustave Roussy, Villejuif, France"},{"name":"Department of Radiotherapy, Gustave Roussy, Villejuif, France"},{"name":"INSERM 1030, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[{"name":"Brachytherapy Unit, Gustave Roussy, Villejuif, France"},{"name":"Department of Radiotherapy, Gustave Roussy, Villejuif, France"},{"name":"INSERM 1030, Gustave Roussy Cancer Campus, Villejuif, France"},{"name":"Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, Br\u00e9tigny-sur-Orge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"2021122506434094600_onco12022-bib-0001","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"2021122506434094600_onco12022-bib-0002","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijrobp.2009.02.077","article-title":"The role of adjuvant radiation in uterine sarcomas","volume":"76","author":"Sampath","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122506434094600_onco12022-bib-0003","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: A review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2021122506434094600_onco12022-bib-0004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijgo.2008.12.008","article-title":"FIGO staging for uterine sarcomas","volume":"104","author":"Prat","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"2021122506434094600_onco12022-bib-0005","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: A Gynecologic Oncology Group Study","volume":"3","author":"Omura","year":"1985","journal-title":"J Clin Oncol"},{"key":"2021122506434094600_onco12022-bib-0006","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mds545","article-title":"A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group","volume":"24","author":"Pautier","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122506434094600_onco12022-bib-0007","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur J Cancer"},{"key":"2021122506434094600_onco12022-bib-0008","first-page":"1111","article-title":"Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas","volume":"32","author":"Sorbe","year":"2008","journal-title":"Int J Oncol"},{"key":"2021122506434094600_onco12022-bib-0009","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/0277-5379(91)90300-3","article-title":"Retrospective analysis of 318 cases of uterine sarcoma","volume":"27","author":"Ol\u00e1h","year":"1991","journal-title":"Eur J Cancer"},{"key":"2021122506434094600_onco12022-bib-0010","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.2147\/OTT.S88186","article-title":"The prognosis factor of adjuvant radiation therapy after surgery in uterine sarcomas","volume":"8","author":"Hou","year":"2015","journal-title":"Onco Targets Ther"},{"key":"2021122506434094600_onco12022-bib-0011","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.brachy.2009.08.014","article-title":"Technical aspects and perspectives of the vaginal mold applicator for brachytherapy of gynecologic malignancies","volume":"9","author":"Magn\u00e9","year":"2010","journal-title":"Brachytherapy"},{"key":"2021122506434094600_onco12022-bib-0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brachy.2014.07.007","article-title":"Adjuvant brachytherapy for endometrial cancer: Advantages of the vaginal mold technique","volume":"14","author":"El Khoury","year":"2015","journal-title":"Brachytherapy"},{"key":"2021122506434094600_onco12022-bib-0013","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0360-3016(03)01561-X","article-title":"Malignant mixed M\u00fcllerian tumors of the uterus: Analysis of patterns of failure, prognostic factors, and treatment outcome","volume":"58","author":"Callister","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122506434094600_onco12022-bib-0014","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1259\/0007-1285-66-791-1009","article-title":"Survival, patterns of spread and prognostic factors in uterine sarcoma: A study of 76 patients","volume":"66","author":"Moskovic","year":"1993","journal-title":"Br J Radiol"},{"key":"2021122506434094600_onco12022-bib-0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"key":"2021122506434094600_onco12022-bib-0016","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"key":"2021122506434094600_onco12022-bib-0017","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1748-717X-8-128","article-title":"Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma","volume":"8","author":"Wong","year":"2013","journal-title":"Radiat Oncol"},{"key":"2021122506434094600_onco12022-bib-0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0360-3016(98)00515-X","article-title":"Impact of radiotherapy on local control and survival in uterine sarcomas: A retrospective study from the Grup Oncologic Catal\u00e0-Occit\u00e0","volume":"44","author":"Ferrer","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122506434094600_onco12022-bib-0019","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/IGC.0b013e3181a1bfbc","article-title":"Prognostic factors in early-stage leiomyosarcoma of the uterus","volume":"19","author":"Pelmus","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"2021122506434094600_onco12022-bib-0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajog.2008.04.019","article-title":"The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma","volume":"199","author":"Wright","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"2021122506434094600_onco12022-bib-0021","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0360-3016(98)00482-9","article-title":"FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy","volume":"43","author":"Logsdon","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122506434094600_onco12022-bib-0022","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2559.2009.03231.x","article-title":"Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients","volume":"54","author":"Abeler","year":"2009","journal-title":"Histopathology"},{"key":"2021122506434094600_onco12022-bib-0023","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1425::AID-CNCR21>3.0.CO;2-3","article-title":"Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma","volume":"88","author":"Pautier","year":"2000","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0204","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0204","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/2\/182\/41913514\/oncolo_22_2_182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/2\/182\/41913514\/oncolo_22_2_182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:45:30Z","timestamp":1640414730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/2\/182\/6420123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,9,18]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0204","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2,1]]},"published":{"date-parts":[[2017,2,1]]}}}